Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis

Circulation. 2004 Sep 14;110(11):1443-9. doi: 10.1161/01.CIR.0000141561.15939.EC. Epub 2004 Aug 30.

Abstract

Background: Comprehension of the pathogenesis of Trypanosoma cruzi-elicited myocarditis is crucial to delineate strategies aimed at ameliorating the inflammation associated with heart dysfunction. The augmented expression of CC chemokines, especially CCL5/RANTES and CCL3/MIP-1alpha, in the hearts of infected mice suggests a role for CC chemokines and their receptors in the pathogenesis of T cruzi-elicited myocarditis.

Methods and results: We report that during the early phase of infection in C3H/HeJ mice infected with 100 blood trypomastigotes of T cruzi, most of the inflammatory cells invading the heart tissue were CD8+ cells and expressed CCR5, a CCL5/RANTES, and CCL3/MIP1-alpha receptor. Furthermore, peripheral blood CD8+ T lymphocytes displayed increased expression of CCR5. These findings led us to use Met-RANTES, a selective CCR1 and CCR5 antagonist, to modulate the acute T cruzi-elicited myocarditis. Met-RANTES treatment did not interfere with parasitism but significantly decreased the numbers of CD4+ and CD8+ T cells, CCR5+, and interleukin-4+ cells invading the heart, paralleling the diminished deposition of fibronectin. Moreover, Met-RANTES treatment resulted in increased survival of infected animals, compared with saline treatment.

Conclusions: These results indicate that the massive influx of CCR5+ cells into cardiac tissue is not crucial for cell-mediated anti-T cruzi immunity but appears to be critical for pathogenesis of T cruzi-elicited myocarditis. Thus, CC chemokine receptors might become an attractive therapeutic target for further evaluation during T cruzi infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CCR5 Receptor Antagonists
  • CD4-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / immunology*
  • Chagas Cardiomyopathy / blood
  • Chagas Cardiomyopathy / drug therapy*
  • Chagas Cardiomyopathy / physiopathology
  • Chemokine CCL2 / biosynthesis
  • Chemokine CCL2 / genetics
  • Chemokine CCL3
  • Chemokine CCL4
  • Chemokine CCL5 / analogs & derivatives*
  • Chemokine CCL5 / antagonists & inhibitors
  • Chemokine CCL5 / metabolism*
  • Chemokine CCL5 / therapeutic use*
  • Chemokines, CC / biosynthesis
  • Chemokines, CC / genetics
  • Chemotaxis, Leukocyte
  • Female
  • Fibronectins / analysis
  • Interleukin-4 / analysis
  • Lymphocyte Activation*
  • Macrophage Inflammatory Proteins / biosynthesis
  • Macrophage Inflammatory Proteins / genetics
  • Macrophage Inflammatory Proteins / metabolism*
  • Mice
  • Mice, Inbred C3H
  • Myocarditis / blood
  • Myocarditis / drug therapy*
  • Myocarditis / parasitology
  • Myocarditis / physiopathology
  • RNA, Messenger / biosynthesis
  • Receptors, CCR1
  • Receptors, CCR5 / biosynthesis
  • Receptors, CCR5 / genetics
  • Receptors, CCR5 / physiology
  • Receptors, Chemokine / antagonists & inhibitors
  • Receptors, Chemokine / physiology

Substances

  • CCR5 Receptor Antagonists
  • Ccl2 protein, mouse
  • Ccl3 protein, mouse
  • Ccl4 protein, mouse
  • Ccr1 protein, mouse
  • Chemokine CCL2
  • Chemokine CCL3
  • Chemokine CCL4
  • Chemokine CCL5
  • Chemokines, CC
  • Fibronectins
  • Macrophage Inflammatory Proteins
  • RANTES, Met-
  • RNA, Messenger
  • Receptors, CCR1
  • Receptors, CCR5
  • Receptors, Chemokine
  • Interleukin-4